Skip to main content
Premium Trial:

Request an Annual Quote

FoxHollow Licenses Rosetta Resolver for Atherosclerosis Project with Merck

NEW YORK, March 13 (GenomeWeb News) - FoxHollow Technologies has licensed the Rosetta Resolver system for research on cardiovascular disease, Rosetta Biosoftware said today.

 

FoxHollow will use the application to correlate genetic profiles of human atherosclerotic plaque samples to develop therapies, according to a statement. The data for analysis comes from a September 2005 pharmacogenomic collaboration between FoxHollow and Merck.

 

Financial details were not released.

 

Rosetta Biosoftware is a business unit of Rosetta Inpharmatics, which is a wholly owned subsidiary of Merck.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.